Exclusive, worldwide rights obtained from two Israeli technology firms covers development and commercialization.

BioLineRx obtained a novel peptide for the treatment of inflammatory diseases from Yissum Research Development Company of the Hebrew University of Jerusalem and Ramot at Tel Aviv University Ltd.

“We believe that BL-4020 offers the potential for a highly effective and safe therapy utilizing a novel mechanism of action,” remarks Morris C. Laster, M.D., CEO of BioLineRx.

BL-4020 is a peptide designed to function as an anti-inflammatory agent in various diseases, such as allergic asthma and colitis. The peptide mimics ManLAM, a protein from the cell surface of Mycobacterium tuberculosis. ManLAM has been shown to modulate the function of the immune system and suppress various inflammatory diseases.

BioLineRx expects that BL-4020, which retains the anti-inflammatory properties of ManLAM, will be effective with low toxicity. In preclinical trials, it was shown to be effective in a wide variety of animal models of inflammation, according to the company.

The worldwide, exclusive license agreement with Yissum and Ramot includes the development and commercialization of BL-4020.

Previous articleAvera Gains Rights to Muscle Paralysis Compounds
Next articleM.D. Anderson Team Identifies Protein that Shields Pancreatic Cancer Cells from Self-Digestion